Parkwood LLC held its position in Mylan N.V. (NASDAQ:MYL) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 13,600 shares of the company’s stock at the end of the second quarter. Parkwood LLC’s holdings in Mylan N.V. were worth $528,000 at the end of the most recent quarter.
A number of other institutional investors have also bought and sold shares of MYL. BlackRock Inc. increased its position in Mylan N.V. by 3,447.5% in the first quarter. BlackRock Inc. now owns 38,822,643 shares of the company’s stock valued at $1,513,696,000 after buying an additional 37,728,274 shares during the period. Pzena Investment Management LLC acquired a new position in Mylan N.V. during the first quarter valued at $283,158,000. TIAA CREF Investment Management LLC increased its position in Mylan N.V. by 187.3% in the first quarter. TIAA CREF Investment Management LLC now owns 4,315,668 shares of the company’s stock valued at $168,268,000 after buying an additional 2,813,653 shares during the period. Morgan Stanley increased its position in Mylan N.V. by 82.6% in the first quarter. Morgan Stanley now owns 4,174,499 shares of the company’s stock valued at $162,765,000 after buying an additional 1,888,905 shares during the period. Finally, Wellington Management Group LLP increased its position in Mylan N.V. by 2.6% in the first quarter. Wellington Management Group LLP now owns 46,373,108 shares of the company’s stock valued at $1,808,088,000 after buying an additional 1,165,852 shares during the period. Hedge funds and other institutional investors own 70.19% of the company’s stock.
Shares of Mylan N.V. (NASDAQ MYL) traded down 4.37% during mid-day trading on Friday, hitting $30.88. 11,080,762 shares of the company were exchanged. The stock has a market cap of $16.52 billion, a PE ratio of 24.96 and a beta of 1.27. The stock’s 50-day moving average price is $37.57 and its 200 day moving average price is $39.05. Mylan N.V. has a 12-month low of $29.58 and a 12-month high of $49.42.
Mylan N.V. (NASDAQ:MYL) last issued its earnings results on Wednesday, August 9th. The company reported $1.10 EPS for the quarter, missing the consensus estimate of $1.18 by $0.08. The firm had revenue of $2.96 billion during the quarter, compared to the consensus estimate of $3 billion. Mylan N.V. had a return on equity of 22.42% and a net margin of 5.51%. The firm’s revenue for the quarter was up 15.7% compared to the same quarter last year. During the same period last year, the business earned $1.16 earnings per share. On average, equities analysts anticipate that Mylan N.V. will post $4.68 EPS for the current fiscal year.
WARNING: This report was first posted by Community Financial News and is owned by of Community Financial News. If you are reading this report on another website, it was copied illegally and reposted in violation of US & international copyright and trademark law. The original version of this report can be accessed at https://www.com-unik.info/2017/08/11/parkwood-llc-holds-position-in-mylan-myl-updated.html.
MYL has been the subject of a number of recent research reports. Deutsche Bank AG lowered their price target on shares of Mylan N.V. from $52.00 to $51.00 and set a “buy” rating for the company in a report on Tuesday, April 18th. Barclays PLC upgraded shares of Mylan N.V. from an “equal weight” rating to an “overweight” rating and lifted their price target for the stock from $47.00 to $50.00 in a report on Monday, May 22nd. Zacks Investment Research upgraded shares of Mylan N.V. from a “sell” rating to a “hold” rating in a report on Tuesday, August 1st. Royal Bank Of Canada reiterated a “sector perform” rating and set a $46.00 price target (down from $48.00) on shares of Mylan N.V. in a report on Monday, April 17th. Finally, Wells Fargo & Company reiterated a “market perform” rating and set a $40.00 price target on shares of Mylan N.V. in a report on Friday, April 14th. Two investment analysts have rated the stock with a sell rating, eleven have issued a hold rating, twelve have issued a buy rating and two have issued a strong buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $47.83.
In other news, President Rajiv Malik sold 25,000 shares of the firm’s stock in a transaction on Friday, June 9th. The stock was sold at an average price of $40.00, for a total value of $1,000,000.00. Following the completion of the sale, the president now directly owns 799,855 shares in the company, valued at $31,994,200. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Anthony Mauro sold 10,000 shares of the firm’s stock in a transaction on Friday, June 9th. The shares were sold at an average price of $40.00, for a total value of $400,000.00. Following the completion of the sale, the insider now owns 140,653 shares of the company’s stock, valued at $5,626,120. The disclosure for this sale can be found here. Corporate insiders own 0.69% of the company’s stock.
About Mylan N.V.
Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.
What are top analysts saying about Mylan N.V.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Mylan N.V. and related companies.